Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherCARDIOVASCULAR PHARMACOLOGY

Block of IKs by the Diuretic Agent Indapamide Modulates Cardiac Electrophysiological Effects of the Class III Antiarrhythmic Drug dl-Sotalol

Céline Fiset, Benoit Drolet, Bettina A. Hamelin and Jacques Turgeon
Journal of Pharmacology and Experimental Therapeutics October 1997, 283 (1) 148-156;
Céline Fiset
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benoit Drolet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bettina A. Hamelin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacques Turgeon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Indapamide is a diuretic agent with direct electrophysiological effects on ionic currents involved in cardiac repolarization. In particular, indapamide blocks the slow component of delayed rectifier potassium current. In contrast, most class III antiarrhythmic agents, such asdl-sotalol, block the rapid component of delayed rectifier potassium current. Computer simulations have suggested potentiation of drug effects on cardiac repolarization by the combined block of the rapid component of delayed rectifier potassium current and the slow component of delayed rectifier potassium current. Therefore, the objective of our study was to evaluate the modulation of cardiac electrophysiological effects of dl-sotalol by indapamide. Two indices of cardiac repolarization, monophasic action potential duration at 90% repolarization and effective refractory period, at two basic cycle lengths (800 and 400 msec) were determined in 24 anesthetized open-chest dogs. In two treatment groups (n = 6/group), data were obtained at base line and every 2 min during steadily increasing concentrations ofdl-sotalol (0–40 μg/ml) either alone or in the presence of indapamide (500 ng/ml). Data were also obtained in dogs receiving either a low-dose (500 ng/ml) or a high-dose (up to 7.5 μg/ml) infusion regimen of indapamide alone. Administration ofdl-sotalol was associated with concentration-dependent increases in monophasic action potential duration at 90% repolarization and effective refractory period, whereas repolarization was only slightly altered by the administration of indapamide alone. However, concentration-response curves of dl-sotalol were shifted to the left in dogs treated with the combination ofdl-sotalol and indapamide, and the EC50 values of dl-sotalol estimated for the prolongation of monophasic action potential duration at 90% repolarization and effective refractory period were decreased 3-fold during the coadministration of both drugs (P < .05 vs. dl-sotalol alone). Thus, under conditions of normal K+ levels, clinically relevant concentrations of indapamide modulate dl-sotalol effects on cardiac repolarization. Additional block of cardiac K+currents, especially the rapid component of delayed rectifier potassium current and the slow component of delayed rectifier potassium current could explain these observations.

Footnotes

  • Send reprint requests to: Dr. Jacques Turgeon, Ph.D., Centre de recherche, Hôpital Laval, 2725 Chemin Ste-Foy, Sainte-Foy, Québec, Canada, G1V 4G5.

  • ↵1 This study was supported by the Medical Research Council of Canada (MT-11876) and by the Heart and Stroke Foundation of Canada (Québec). J.T. is the recipient of a scholarship from the Joseph C. Edwards Foundation. B.A.H. is the recipient of a scholarship from the Fonds de la Recherche en Santé du Québec. During the course of this study, C.F. was the recipient of a studentship from the Medical Research Council and Pharmaceutical Manufacturers Association of Canada. B.D. is the recipient of studentships from Merck Frosst Canada and the Fonds pour la Formation de Chercheurs et l’Aide àla Recherche (FCAR).

  • Abbreviations:
    BCL400
    a basic cycle length of stimulation of 400 msec
    BCL800
    a basic cycle length of stimulation of 800 msec
    EADs
    early afterdepolarizations
    ERP
    effective refractory period
    IK
    delayed rectifier potassium current
    IKr
    the rapid component of IK
    IKs
    the slow component of IK
    MAPD90
    monophasic action potential duration at 90% repolarization
    • Received December 12, 1996.
    • Accepted June 25, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 283, Issue 1
1 Oct 1997
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Block of IKs by the Diuretic Agent Indapamide Modulates Cardiac Electrophysiological Effects of the Class III Antiarrhythmic Drug dl-Sotalol
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherCARDIOVASCULAR PHARMACOLOGY

Block of IKs by the Diuretic Agent Indapamide Modulates Cardiac Electrophysiological Effects of the Class III Antiarrhythmic Drug dl-Sotalol

Céline Fiset, Benoit Drolet, Bettina A. Hamelin and Jacques Turgeon
Journal of Pharmacology and Experimental Therapeutics October 1, 1997, 283 (1) 148-156;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherCARDIOVASCULAR PHARMACOLOGY

Block of IKs by the Diuretic Agent Indapamide Modulates Cardiac Electrophysiological Effects of the Class III Antiarrhythmic Drug dl-Sotalol

Céline Fiset, Benoit Drolet, Bettina A. Hamelin and Jacques Turgeon
Journal of Pharmacology and Experimental Therapeutics October 1, 1997, 283 (1) 148-156;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • RESULTS
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Preconditioning of Rat Heart with Monophosphoryl Lipid A: A Role for Nitric Oxide
  • TAS-301, an Inhibitor of Smooth Muscle Cell Migration and Proliferation, Inhibits Intimal Thickening after Balloon Injury to Rat Carotid Arteries
  • Identification of Low Molecular Weight GP IIb/IIIa Antagonists That Bind Preferentially to Activated Platelets
Show more CARDIOVASCULAR PHARMACOLOGY

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics